Core Viewpoint - OR Royalties Inc. has announced a normal course issuer bid (NCIB Program) to repurchase up to 9,399,294 common shares, representing approximately 5% of the issued shares, with a total budget of C$28.0 million for 2025 [1][6][7]. Summary by Sections NCIB Program Details - The NCIB Program is approved by the Toronto Stock Exchange (TSX) and allows the company to acquire shares through open market transactions or other permitted means [1][2]. - Repurchases may start on December 12, 2025, and will end on December 11, 2026, with daily purchases limited to 107,496 shares [3]. - The purchase price for shares will be the market price at the time of acquisition, plus any applicable brokerage fees [4]. Rationale for Share Repurchase - The Board of Directors believes that the market price does not reflect the underlying value of the company, and repurchasing shares will benefit remaining shareholders by increasing their proportional interest [5]. Historical Context - Under the previous NCIB Program, which ran from December 12, 2024, to December 11, 2025, the company repurchased 228,183 shares at an average price of approximately C$45.83, totaling C$28.0 million in 2025 [7].

Core Insights - EUDA Health Holdings Limited is launching an integrated digital health and rewards platform utilizing a utility cryptocurrency called QB, set to launch in January 2026 [1][2] - The QB cryptocurrency will facilitate payments, rewards, and access to EUDA's healthcare products and services, enhancing the connection between healthcare and digital finance [2][3] - This initiative aims to transform healthcare engagement into tangible economic and health benefits, promoting a unified ecosystem that combines wellness products and digital assets [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [4] - The company aims to lead the transformation from reactive medical treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [4]

KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation from healthy volunteers to atopic dermatitis (AD) patients KT-621 achieved strong reductions in disease-relevant Type 2 biomarkers in blood, including TARC (median reduction of 74% in patients with baseline TARC levels comparable to dupilumab AD studies), Eotaxin-3, IL-31, IgE, and in core Type 2 inflammation and ...

Strong sulphur and third-party processing revenue support robust cash flow and debt reduction targets for 2026; successful execution of strategic plan delivers exceptional shareholder returnsNot For Distribution to United States News Wire Services or Dissemination in United States CALGARY, Alberta, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cavvy Energy Ltd. (“Cavvy” or the “Company”) (TSX:CVVY) is pleased to release 2026 guidance, highlighted by accelerated debt reduction targeting $50 million and an increase in ne ...

Represents first contract under Approved Supplier Status with Global Aerospace LeaderMONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of a half-tonne contract with a Global Aerospace Leader for the supply of titanium metal powder produced by PyroGenesis’ NexGen™ plas ...

ANDOVER, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, will participate in this week’s Association of Old Crows (AOC) International Symposium and Convention, showcasing the company’s expanding portfolio of electronic warfare (EW) capabilities and sharing key insights during conference sessions. AOC 2025 is the premier event for electronic warfare, electromagnetic spectrum operati ...

VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Xali Gold Corp. (TSXV:XGC) ("Xali Gold” or the “Company”) is pleased to announce that it has filed the National Instrument 43-101 (“NI 43-101”) compliant report titled “Technical Report Pico Machay Gold Deposit, Huancavelica Province, Peru” effective November 18th, 2025 and dated December 4th, 2025 (the “Technical Report”) on SEDAR+. This Report was prepared by David Thomas, P.Geo., of DKT Geosolutions Inc., on behalf of Xali Gold to comply with ...

Group 1 - Cardiff Oncology, Inc. is a clinical-stage biotechnology company focused on developing novel therapies through PLK1 inhibition for various cancers [2] - The company's lead asset, onvansertib, is being evaluated in combination with standard of care therapeutics for indications such as RAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer [2] - Cardiff Oncology will present at Sidoti's Year-End Virtual Investor Conference on December 11, 2025, with CEO Mark Erlander as the presenter [1] Group 2 - The company's development strategy aims to target tumor vulnerabilities to overcome treatment resistance and provide superior clinical benefits compared to standard of care alone [2] - Interested parties can register for the live webcast of the conference through the Cardiff Oncology website [1]

NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) -- eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, is reporting the below selected monthly business metrics for November 2025. Assets under Administration (AUA) were $18.8B, up 9% year-over-year.Funded accounts were 3.79M, up 10% year-over-year.*Capital Markets/ECC Activity Total number of trades was 46.3M, up 16% year-over-year; Invested amount per trade was $269, down 13% year-over-year; Crypto Activity Total number ...

Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage the 505(b)(2) regulatory pathway for new drug approvals which has the potential to shorten the review timeline for AXPAXLI If approved, AXPAXLI could be the first TKI to be commercialized in wet AMD, with a potential superiority label and best-in-class durability BEDFORD, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Oc ...